Skip to main content
HIMS logo

Hims & Hers Health, Inc. (HIMS) Stock: Price, Forecast & Analyst Target

Hims & Hers Health, Inc. (HIMS) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $16.02 (-6.04%), as of the Nov 19, 2026 trading session; market cap $3.76B.

Educational signal · not a buy or sell recommendation · How to read this

$16.02 −$1.03 (-6.04%) Market Cap $3.76B

Hims & Hers Health, Inc. · HIMS · NYSE · Healthcare · Medical - Care Facilities

Research dated 2026-09-13: The company operates a telehealth platform connecting patients with licensed clinicians for prescriptions and over-the-counter wellness products. Profitability has vanished in the most recent quarters despite sustained revenue growth, and the question is whether this signals a structural problem with unit economics or a temporary squeeze that resolves as the platform scales.

Price as of Nov 19, 2026

Key Statistics

31 of 100

MoonshotScore v2 · Hims & Hers Health (HIMS)

Weak
Business Quality Solid (69)
Financial Safety Fragile (8)
Valuation Full (53)
Growth Durability Flat (51)
Momentum Slipping (37)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z 1.18 · Piotroski F 2
  • ROE -40.8% · ROA -4.0% · current ratio 0.92

Holding back: balance-sheet strain

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HIMS (57 recorded, newest six shown)
RecordedScoreBand
32Weak
32Weak
32Weak
32Weak
31Weak
31Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$16.02
Change on the day-6.04%
52-week range$13.74–$40.99
Market capitalisation$3.76B—
Price / earnings (trailing)50.00
Shares traded on the day13.42M
Beta (volatility vs the S&P 500)2.5

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $15, high $50, latest $16. $50 $15 high $50 Oct 17, 2025 Nov 19, 2026 · $16 $50Oct 17, 2025$45Oct 31, 2025$37Nov 14, 2025$40Nov 28, 2025$37Dec 12, 2025$34Dec 26, 2025$32Jan 9, 2026$30Jan 23, 2026$23Feb 6, 2026$16Feb 20, 2026$16Mar 6, 2026$22Mar 20, 2026$19Apr 2, 2026$29Apr 17, 2026$27May 1, 2026$25May 15, 2026$26May 29, 2026$27Jun 12, 2026$34Jun 26, 2026$34Jul 10, 2026$28Jul 24, 2026$32Aug 7, 2026$34Aug 21, 2026$28Sep 4, 2026$28Sep 18, 2026$29Oct 2, 2026$28Oct 16, 2026$28Oct 30, 2026$20Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Hims & Hers Health (HIMS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Hims & Hers Health (HIMS), and what does it report?

Short answer · as of

The platform generates revenue from virtual consultations billed to insurance and patient copays alongside direct-to-consumer sales of medications and wellness products.

The reporting combines these into aggregate revenue, making it difficult for investors to isolate high-margin consultations from lower-margin product sales.

The company carries substantial debt while operating at gross margins typical of commodity retail.

2 · Latest results

What do the latest results show for Hims & Hers Health (HIMS)?

The most recent quarter showed operating losses widen even as revenue accelerated, meaning incremental sales generated less operating profit than the prior period. Selling and general expenses contracted as a percentage of revenue, but research and development expense rose, suggesting the company is investing in competitive differentiation while profitability deteriorates.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$599M$16M$0.06 (diluted)
Q4 FY2025$618M$21M$0.08 (diluted)
Q1 FY2026$608M-$92M-$0.40 (diluted)
Q2 FY2026$753M-$86M-$0.37 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Hims & Hers Health (HIMS)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Gross margins remain robust, providing cushion for operating expenses, but the balance sheet shows liquidity metrics that fall short of prudent standards and leverage ratios that exceed comfortable thresholds, meaning the company has limited liquid assets to cover near-term obligations if revenue stalls.

The most pressing risk is that revenue growth masks deteriorating unit economics in customer acquisition or retention.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.18 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-40.8%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Hims & Hers Health (HIMS)?

Short answer · as of

Current published price targets run low $24.00 · high $40.00 · consensus $31.00 · median $32.00 against a quoted price of $16.02 (as of Nov 19, 2026).

Insiders have sold continuously over the most recent period with no offsetting purchases, which typically signals weak conviction about near-term recovery. Watch whether the next reported quarter returns to profitability or the loss persists, because sustained operating losses would suggest recent earnings swings are not seasonal noise.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Hims & Hers Health compare with its peers?

Short answer

Hims & Hers Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Most digital health platforms operate under the same margin and cash-consumption trade-off: either they push through to profitability by cutting customer acquisition spending, or they accelerate acquisition and defer profits. Hims is distinctive in its exposure to over-the-counter product sales, which are lower margin than prescription services but can build retail loyalty. That mix is unique among telehealth peers and represents the company's strategic differentiation.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Addus HomeCare Corporation (ADUS) Same industry, near in market value$120.85 Nov 18, 2026$2.25B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Named competitor$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
LifeStance Health Group, Inc. (LFST) Same industry, near in market value$13.77 Nov 18, 2026$5.24B92 5-pillar Nov 18, 2026
Option Care Health, Inc. (OPCH) Same industry, near in market value$31.61 Nov 19, 2026$4.74B85 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Pediatrix Medical Group, Inc. (MD) Same industry, near in market value$29.94 Nov 19, 2026$2.34B82 5-pillar Nov 18, 2026
National HealthCare Corporation (NHC) Same industry, near in market value$201.60 Nov 18, 2026$3.16B76 5-pillar Nov 18, 2026
Aveanna Healthcare Holdings Inc. (AVAH) Same industry, near in market value$10.70 Nov 19, 2026$2.34B75 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Named competitor$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
BioMarin Pharmaceutical Inc. (BMRN) Named competitor$61.43 Nov 18, 2026$11.9B58 5-pillar Nov 18, 2026
MiniMed Group, Inc. Common Stock (MMED) Same industry, near in market value$16.26 Nov 19, 2026$4.57B38 5-pillar Nov 18, 2026
Surgery Partners, Inc. (SGRY) Same industry, near in market value$26.69 Nov 19, 2026$3.49B35 5-pillar Nov 18, 2026
Hims & Hers Health (HIMS) — this page$16.02$3.76B31

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$24.00 – $40.00
Consensus target
$31.00
Median target
$32.00

Consensus record · Captured .

Measured against a quoted price of $16.02 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
98
Identified insiders
17
Purchases
0
Sales
16
Other transactions
82

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HIMS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HIMS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Hims & Hers Health (HIMS)?

Read these with our analysis →

Hims & Hers Health Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

How does Hims make money from sexual health and hair care products?

These are over-the-counter categories sold directly through the platform alongside prescription consultations, expanding the customer's lifetime value by creating additional purchasing occasions. The company's portfolio combines recurring prescription revenue with non-recurring product sales.

What does the recent insider selling tell us?

Over the most recent period, insiders have executed net sales with no corresponding purchases, with the heaviest activity occurring most recently. This pattern typically reflects either tax-motivated rebalancing or loss of conviction about near-term stock recovery. Insiders who are confident in the business trajectory typically maintain consistent ownership levels.

Why did profitability evaporate in the latest quarters even as revenue accelerated?

Operating expenses remain partially fixed, and the most recent periods saw elevated spending on research and development alongside continued deployment of sales and marketing infrastructure. The deterioration suggests the company prioritized market position over near-term earnings, betting that scale will eventually drive margin improvement.

Is the balance sheet stable enough to support current revenue trajectory?

Liquid assets cover less than would be required for an extended revenue decline, while total debt exceeds liquid resources significantly, meaning the company relies on sustained cash generation from operations. A sharp downturn in revenue growth would force the company to issue equity or cut spending, both dilutive to current shareholders.

What is the HIMS stock price today?

The last price recorded for Hims & Hers Health, Inc. (HIMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the HIMS price target?

The analyst consensus price target for Hims & Hers Health, Inc. (HIMS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 1. What is Hims & Hers Health (HIMS), and what does it report?: Business description; Quarterly income statement (USD thousands); Cash, investments and debt
  • 2. What do the latest results show for Hims & Hers Health (HIMS)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Hims & Hers Health (HIMS)?: Trailing twelve-month ratio set; Cash and investment components; Distress and quality screens
  • 4. What should you watch next at Hims & Hers Health (HIMS)?: Insider transactions, last 180 days; Next earnings report; Reported versus estimated, last 8 quarters
  • 5. How does Hims & Hers Health compare with its peers?: Business description; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: How does Hims make money from sexual health and hair care products?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: What does the recent insider selling tell us?: Insider transactions, last 180 days; Named officers; Largest 5 institutional holders
  • FAQ: Why did profitability evaporate in the latest quarters even as revenue accelerated?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • FAQ: Is the balance sheet stable enough to support current revenue trajectory?: Cash and investment components; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.